Table 2 Risk of ILD in different IIM subgroups and myositis antibody categories

IIM subgroup (n)

DM (52)

5.24 (0.84–32.81)

0.077^*

4.78 (0.77–29.90)

0.095^*

ASS (63)

67.79 (10.07-456.54)

< 0.001^*

52.28 (7.67-356.47)

< 0.001^*

IMNM (16)

0.87 (0.08–10.15)

0.912^*

0.88 (0.08–10.10)

0.917^*

Overlap myositis (44)

3.46 (0.54–22.38)

0.192^*

2.80 (0.30-25.87)

0.365^*

PM (14)

ref.

-

ref.

-

Antibody positivity (n) vs. negativity (n)

Any MSAs (102 vs. 87)

7.01 (3.66–13.41)

< 0.001

6.84 (3.39–13.77)

< 0.001

Any MSAs and Ro-52 antibodies (53 vs. 136)

22.24 (8.26–59.93)

< 0.001

20.86 (7.63–57.08)

< 0.001

Anti-ARS antibodies (63 vs. 126)

15.60 (6.97–34.93)

< 0.001

14.64 (6.43–33.33)

< 0.001

Anti-ARS and Ro-52 antibodies (42 vs. 147)

40.00 (9.28–172.40)

< 0.001

38.39 (8.83–167.00)

< 0.001

Anti-MDA5 antibodies (12 vs. 177)

2.37 (0.69–8.16)

0.171

2.86 (0.75–10.86)

0.124

Anti-MDA5 and Ro-52 antibodies (5 vs. 184)

13.09 (0.54-316.51)

0.114^*

10.09 (0.39-260.64)

0.163^*

Anti-Ro-52 antibodies (76 vs. 113)

7.59 (3.92–14.71)

< 0.001

8.42 (4.14–17.13)

< 0.001